RE:Too Soon eh!Yes, TLT is very frustrating. Besides being hammered by the halt of TLT's application to the FDA that took 6 months to iron out, we were also slammed by COVID-19 which caused a temporary cessation of the Phase 2 clinical trial. We don't know when new patients will be brought in and treated. And seems the patients treated so far may not get the second treatment at 6 months. It may be that all patients treated and making the 1 year mark post treatment might not be completed until 2022. I think the market has spoken that currently there is little confidence in TLT. I think given the way it currently trades, previous thoughts by some that this stock would reach $100 is but an unrealistic dream. I want to see 60 cents and then maybe if things all went well in 2021 or 2022 we could see TLT at a couple of bucks. Because with this delay TLT may well run out of money before the end of the current Ph 2 study and have to do another financing which will create far too many outstanding shares to create the value we are all waiting for. So I will continue to hold and hope that in the next year or so my frustration will be rewarded by at least 10 times the current value.